BIAF Company Profile and Key Details

bioAffinity Technologies, Inc. generated EPS of -$20.87 over the past year. Five-year average earnings growth is -10.71%. The latest quarter delivered EPS of -$0.64. The next quarter is forecast at $nan. Next year's EPS is expected at -$27.63. bioAffinity Technologies, Inc. earnings surprise history is a mixed track record. The quarter that ended August 07, 2026, missed forecasts by -69.52%. The prior quarter beat by -66.25%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 15, 2025.

BIAF has shown mixed momentum, gaining 3.15% over the past week and -55.44% over the past quarter, though year-to-date performance is up 11.02%. Short-term trend indicators are bullishly aligned (SMA20 0.0%, SMA50 -12.37%, SMA200 -78.29%). The stock’s 14-day RSI is 46.25 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.76% below its high and over 50.07% above its low. Average 10-day trading volume of 6.58 million shares is significantly above the 3-month average of 763.64 thousand, indicating heightened recent market interest.

bioAffinity Technologies, Inc. has 540.12 thousand shares outstanding. The public float is 532.21 thousand shares, elevated short interest at 4.88% of float. This equals 21.80 thousand shares. The short ratio is 0.85 days. Institutional investors hold 5.3% of the float. Insiders own 1.85%. Rubin Gary D holds 408.12 thousand shares, Zannes Maria has 16.33 thousand shares and KNIGHT PETER S has 8.16 thousand shares.

bioAffinity Technologies, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.13. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that bioAffinity Technologies, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -45.07%, with price expected at $3.62 by September 15, 2026, within a range of $3.04 to $4.23 3-Month Outlook: Projected fall of -99.39%, reaching $0.04 by November 27, 2026, with a range of $0.00 to $7.21. 1-Year Outlook: Projected loss of -90.14%, with price at $0.65 by September 01, 2027, within a range of $0.00 to $15.88.

bioAffinity Technologies, Inc. (NASDAQ:BIAF) shares are up 11.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows bioAffinity Technologies, Inc. trading at a premium to the broader market with a P/E of -0.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.00, suggesting -8.95% downside. Our AI forecast model points to short-term weakness (-45.07% over two weeks), a medium-term fall (-99.39% over three months), and a longer-term loss (-90.14% over one year), with expected trading ranges indicating moderate volatility.

bioAffinity Technologies, Inc. (NASDAQ:BIAF) closed at $6.59 USD, gaining $2.03 (44.52%) from the previous close of $4.56. The stock is currently mid-range between its 52-week high and low $4.56 and $202.50. With a market capitalization of about $2.76 million, bioAffinity Technologies, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.05). Key stats such as the average daily volume over the past year has been around 221.26 thousand shares, trading with heavier-than-usual volume. Headquartered in San Antonio, TX, bioAffinity Technologies, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Maria Zannes, the company employs approximately 57 people and listed since September 01, 2022. As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer.

bioAffinity Technologies, Inc. trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 0.49 and a price-to-book ratio of 0.64 suggesting the stock is closer to book value. The P/FCF stands at -0.25, also above market averages.